Literature DB >> 23125012

Current and future immunomodulation strategies to restore tolerance in autoimmune diseases.

Jeffrey A Bluestone1, Hélène Bour-Jordan.   

Abstract

Autoimmune diseases reflect a breakdown in self-tolerance that results from defects in thymic deletion of potentially autoreactive T cells (central tolerance) and in T-cell intrinsic and extrinsic mechanisms that normally control potentially autoreactive T cells in the periphery (peripheral tolerance). The mechanisms leading to autoimmune diseases are multifactorial and depend on a complex combination of genetic, epigenetic, molecular, and cellular elements that result in pathogenic inflammatory responses in peripheral tissues driven by self-antigen-specific T cells. In this article, we describe the different checkpoints of tolerance that are defective in autoimmune diseases as well as specific events in the autoimmune response which represent therapeutic opportunities to restore long-term tolerance in autoimmune diseases. We present evidence for the role of different pathways in animal models and the therapeutic strategies targeting these pathways in clinical trials in autoimmune diseases.

Entities:  

Mesh:

Year:  2012        PMID: 23125012      PMCID: PMC3536337          DOI: 10.1101/cshperspect.a007542

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Biol        ISSN: 1943-0264            Impact factor:   10.005


  196 in total

1.  Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists.

Authors:  Suzanne Mandala; Richard Hajdu; James Bergstrom; Elizabeth Quackenbush; Jenny Xie; James Milligan; Rosemary Thornton; Gan-Ju Shei; Deborah Card; CarolAnn Keohane; Mark Rosenbach; Jeffrey Hale; Christopher L Lynch; Kathleen Rupprecht; William Parsons; Hugh Rosen
Journal:  Science       Date:  2002-03-28       Impact factor: 47.728

2.  Effect of heat shock protein peptide DiaPep277 on beta-cell function in paediatric and adult patients with recent-onset diabetes mellitus type 1: two prospective, randomized, double-blind phase II trials.

Authors:  Nanette C Schloot; Guido Meierhoff; Csaba Lengyel; Gyözö Vándorfi; József Takács; Pál Pánczél; László Barkai; László Madácsy; Tamás Oroszlán; Peter Kovács; Gábor Sütö; Tadej Battelino; Nora Hosszufalusi; György Jermendy
Journal:  Diabetes Metab Res Rev       Date:  2007-05       Impact factor: 4.876

3.  Polyclonal rabbit antithymocyte globulin triggers B-cell and plasma cell apoptosis by multiple pathways.

Authors:  Martin S Zand; Thuong Vo; Jennifer Huggins; Raymond Felgar; Jane Liesveld; Tina Pellegrin; Adel Bozorgzadeh; Ignacio Sanz; Benjamin J Briggs
Journal:  Transplantation       Date:  2005-06-15       Impact factor: 4.939

4.  Differential induction of IgE-mediated anaphylaxis after soluble vs. cell-bound tolerogenic peptide therapy of autoimmune encephalomyelitis.

Authors:  Cassandra E Smith; Todd N Eagar; Jack L Strominger; Stephen D Miller
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-27       Impact factor: 11.205

5.  Chromogranin A is an autoantigen in type 1 diabetes.

Authors:  Brian D Stadinski; Thomas Delong; Nichole Reisdorph; Richard Reisdorph; Roger L Powell; Michael Armstrong; Jon D Piganelli; Gene Barbour; Brenda Bradley; Frances Crawford; Philippa Marrack; Sushil K Mahata; John W Kappler; Kathryn Haskins
Journal:  Nat Immunol       Date:  2010-02-07       Impact factor: 25.606

6.  Structure of a human autoimmune TCR bound to a myelin basic protein self-peptide and a multiple sclerosis-associated MHC class II molecule.

Authors:  Yili Li; Yuping Huang; Jessica Lue; Jacqueline A Quandt; Roland Martin; Roy A Mariuzza
Journal:  EMBO J       Date:  2005-08-04       Impact factor: 11.598

7.  Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial.

Authors:  Kirsti Näntö-Salonen; Antti Kupila; Satu Simell; Heli Siljander; Tiina Salonsaari; Anne Hekkala; Sari Korhonen; Risto Erkkola; Jukka I Sipilä; Lotta Haavisto; Marja Siltala; Juhani Tuominen; Jari Hakalax; Heikki Hyöty; Jorma Ilonen; Riitta Veijola; Tuula Simell; Mikael Knip; Olli Simell
Journal:  Lancet       Date:  2008-09-22       Impact factor: 79.321

8.  Selective stimulation of T cell subsets with antibody-cytokine immune complexes.

Authors:  Onur Boyman; Marek Kovar; Mark P Rubinstein; Charles D Surh; Jonathan Sprent
Journal:  Science       Date:  2006-02-16       Impact factor: 47.728

9.  Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway.

Authors:  Brian T Fife; Indira Guleria; Melanie Gubbels Bupp; Todd N Eagar; Qizhi Tang; Helene Bour-Jordan; Hideo Yagita; Miyuki Azuma; Mohamed H Sayegh; Jeffrey A Bluestone
Journal:  J Exp Med       Date:  2006-11-20       Impact factor: 14.307

10.  Defects in IL-2R signaling contribute to diminished maintenance of FOXP3 expression in CD4(+)CD25(+) regulatory T-cells of type 1 diabetic subjects.

Authors:  S Alice Long; Karen Cerosaletti; Paul L Bollyky; Megan Tatum; Heather Shilling; Sheng Zhang; Zhong-Yin Zhang; Catherine Pihoker; Srinath Sanda; Carla Greenbaum; Jane H Buckner
Journal:  Diabetes       Date:  2009-10-29       Impact factor: 9.461

View more
  25 in total

1.  T-cell tolerance: central and peripheral.

Authors:  Yan Xing; Kristin A Hogquist
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-06-01       Impact factor: 10.005

Review 2.  Genomics of lymphoid malignancies reveal major activation pathways in lymphocytes.

Authors:  Birgit Knoechel; Jens G Lohr
Journal:  J Autoimmun       Date:  2013-07-21       Impact factor: 7.094

Review 3.  Fetal regulatory T cells and peripheral immune tolerance in utero: implications for development and disease.

Authors:  Trevor D Burt
Journal:  Am J Reprod Immunol       Date:  2013-02-25       Impact factor: 3.886

Review 4.  T cells in the control of organ-specific autoimmunity.

Authors:  Jeffrey A Bluestone; Hélène Bour-Jordan; Mickie Cheng; Mark Anderson
Journal:  J Clin Invest       Date:  2015-05-18       Impact factor: 14.808

5.  Bone Marrow Mesenchymal Stromal Cells Induce Proliferative, Cytokinic and Molecular Changes During the T Cell Response: The Importance of the IL-10/CD210 Axis.

Authors:  Mehdi Najar; Gordana Raicevic; Hussein Fayyad-Kazan; Cécile De Bruyn; Dominique Bron; Michel Toungouz; Laurence Lagneaux
Journal:  Stem Cell Rev Rep       Date:  2015-06       Impact factor: 5.739

Review 6.  Treatment of neuromyelitis optica: state-of-the-art and emerging therapies.

Authors:  Marios C Papadopoulos; Jeffrey L Bennett; Alan S Verkman
Journal:  Nat Rev Neurol       Date:  2014-08-12       Impact factor: 42.937

7.  ILDR2-Fc Is a Novel Regulator of Immune Homeostasis and Inducer of Antigen-Specific Immune Tolerance.

Authors:  Joseph R Podojil; Iris Hecht; Ming-Yi Chiang; Ilan Vaknin; Inbal Barbiro; Amit Novik; Eyal Neria; Galit Rotman; Stephen D Miller
Journal:  J Immunol       Date:  2018-02-05       Impact factor: 5.422

8.  Anti-inflammatory roles of p38α MAPK in macrophages are context dependent and require IL-10.

Authors:  Abbas Raza; Jessica W Crothers; Mahalia M McGill; Gary M Mawe; Cory Teuscher; Dimitry N Krementsov
Journal:  J Leukoc Biol       Date:  2017-09-06       Impact factor: 4.962

9.  Discerning Risk of Disease Transition in Relatives of Systemic Lupus Erythematosus Patients Utilizing Soluble Mediators and Clinical Features.

Authors:  Melissa E Munroe; Kendra A Young; Diane L Kamen; Joel M Guthridge; Timothy B Niewold; Karen H Costenbader; Michael H Weisman; Mariko L Ishimori; Daniel J Wallace; Gary S Gilkeson; David R Karp; John B Harley; Jill M Norris; Judith A James
Journal:  Arthritis Rheumatol       Date:  2017-03       Impact factor: 10.995

10.  Multipeptide-coupled nanoparticles induce tolerance in 'humanised' HLA-transgenic mice and inhibit diabetogenic CD8+ T cell responses in type 1 diabetes.

Authors:  Xinyu Xu; Lingling Bian; Min Shen; Xin Li; Jing Zhu; Shuang Chen; Lei Xiao; Qingqing Zhang; Heng Chen; Kuanfeng Xu; Tao Yang
Journal:  Diabetologia       Date:  2017-09-08       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.